Systemic scleroderma treatment market

Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Mar 2022
CMI4641
164 Pages
Excel & Pdf
Pharmaceutical

Summary

Scleroderma, also known as sclerosis is a rare, chronic disorder involving overproduction and accumulation of collagen in the tissues of the body. Scleroderma majorly affects skin but is not limited to the skin and also affects several major internal organs such as kidney, lungs, heart, and others. The condition wherein thickening of tissues is seen in the skin as well as internal organs is known as systemic scleroderma. Systemic scleroderma causes tightening and hardening of patches of skin which may lead to restricted movement of the affected area. The number and size of patches may vary depending upon the severity of systemic scleroderma disease. Raynaud's disease which causes pain and numbness in fingers or toes in response to cold temperature, is one of the earliest signs of systemic scleroderma. Systemic scleroderma may affect gastrointestinal tract and lead to cramps, diarrhea, constipation, heartburn, and lack of proper absorption of nutrients from the food into the body cells. Systemic scleroderma can become life-threatening if untreated at the right time.

The global systemic scleroderma treatment market is estimated to be valued at US$ 1,520.1 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Figure 1. Global Systemic Scleroderma Treatment Market Share (%), By Region, 2021

The increasing prevalence of scleroderma is expected to drive the growth of the global systemic scleroderma treatment market over the forecast period.

For instance, according to an article published by the Journal of Managed Care & Specialty Pharmacy in December 2020, the prevalence of systemic scleroderma increased from 7.8 per 100,000 in 2011 to 24.3 per 100,000 people in 2016 in the U.S and is expected to further increase in the near future.

Systemic Scleroderma Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,520.1 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	4.2 %	2028 Value Projection:	US$ 2,027.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors) By Disease Type: Limited Systemic Sclerosis, Diffused Systemic Sclerosis, Systemic Sclerosis Sine Scleroderma By Route of Administration: Oral, Parenteral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC
Growth Drivers:	Increasing prevalence of scleroderma Increasing products approval and launches by market players
Restraints & Challenges:	Lack of a standard framework for evaluating systemic scleroderma therapeutics Failure of clinical trials associated with development of systemic scleroderma therapeutics

Figure 2. Global Systemic Scleroderma Treatment Market Value (US$ Mn), By Drug Class, 2021

The increasing research and development activities for the development of novel therapeutics for the treatment of scleroderma is expected to drive the market growth over the forecast period.

For instance, according to study results published in the Journal of Rheumatology in March 2017, Imatinib Mesylate (Gleevec), an oral chemotherapy medication showed positive results to be used in the treatment of diffuse cutaneous systemic sclerosis. Imatinib Mesylate (Gleevec) is manufactured by Novartis Pharmaceuticals, a Switzerland based pharmaceutical company.

Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of scleroderma, which is expected to drive growth of the global systemic scleroderma treatment market over the forecast period.

For instance, in September 2019, Boehringer Ingelheim International GmbH, a Germany based pharmaceutical company received the U.S. Food and Drug Administration Approval for Ofev (nintedanib), a drug which is to be used to treat patients with systemic sclerosis associated interstitial lung disease.

Global Systemic Scleroderma Treatment Market – Impact of Coronavirus (Covid-19) Pandemic

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 211 million population leading to more than 4.4 million deaths as of August 22, 2021. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, recent studies have shown association of COVID-19 with systemic scleroderma and this is expected to show a positive result on the overall growth of the scleroderma treatment market during the pandemic.

For instance, according to a research study conducted in Italy and published by the Lancet Rheumatology journal in March 2021, higher prevalence of COVID-19 has been reported in patients suffering with systemic sclerosis related interstitial lung involvement than in those without it. Moreover, the same study reports high death rate among COVID-19 patients suffering from systemic sclerosis and concludes that risk of severe COVID-19 is high in patients suffering from systemic sclerosis.

Global Systemic Scleroderma Treatment Market - Restraint

The lack of a standard framework for evaluating systemic scleroderma therapeutics and clinical trial failure are the factors that are expected to hinder growth of the global systemic scleroderma treatment market over the forecast period. For instance, in September 2020, Lenabasum, an oral cannabinoid-2 agonist manufactured by Corbus Pharmaceuticals Holdings Inc., a U.S. based clinical stage pharmaceutical company failed to show positive phase III efficacy in treatment of diffuse cutaneous systemic sclerosis despite showing benefits in phase II clinical trial results.

Key Players

Major players operating in the global systemic scleroderma treatment market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene Corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC

Table of Content

Table of Contents

*Browse 33 market data tables and 24 figures on "Systemic Scleroderma Treatment Market” - Global forecast to 2028

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global systemic scleroderma treatment market during the forecast period (2021-2028)?

The global systemic scleroderma treatment market size is estimated to be valued at US$ 1,520.1 million in 2021 and is expected to exhibit a CAGR of 4.2% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing prevalence of scleroderma and increasing research and development activities for the development of novel therapeutics for the treatment of scleroderma are expected to drive the market growth over the forecast period.

Which is the leading drug class segment in the market?

Immunosuppressors segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factors hampering growth of the market include the lack of a standard framework for evaluating systemic scleroderma therapeutics and clinical trial failure.

Which are the major players operating in the market?

Major players operating in the market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC